Description: Davita hit its 23rd new 52-week low on Tuesday. Its stock is now within a few dollars of trading in double digits. That’s not a good thing, given that its share price was nearly $180 a year ago.

Description: DaVita HealthCare (DVA) closed the most recent trading day at $104.47, moving 5.11% from the previous trading session.

Description: NORTHAMPTON, MA / ACCESS Newswire / January 13, 2026 / For many in under-resourced communities, barriers such as unreliable transportation, language, insufficient insurance coverage and limited access to trusted information often put basic healthcare ...

Description: With no single headline event driving attention, DaVita (DVA) is drawing interest as investors weigh its recent share performance, business scale, and profitability against current expectations embedded in the stock price. See our latest analysis for DaVita. DaVita’s recent share price softness, with a 30 day share price return of a 3.5% decline and a 1 year total shareholder return of a 26.87% decline, suggests momentum has faded after stronger 3 year total shareholder returns of 43.94%. If...

Description: DaVita HealthCare (DVA) reached $111.01 at the closing of the latest trading day, reflecting a -3.23% change compared to its last close.

Description: NORTHAMPTON, MA / ACCESS Newswire / January 2, 2026 / As chronic disease rates climb[1], the U.S. faces a critical shortage of nurses - creating an urgent need for innovative solutions in healthcare education and workforce development.[2] As DaVita ...

Description: Ted Weschler, 64, is a value-oriented investor who joined Berkshire Hathaway as an investment manager in 2012.

Description: Ted Weschler, 64, is a value-oriented investor who joined Berkshire Hathaway as an investment manager in 2012.

Description: AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of November 30, 2025.

Description: The much-anticipated CEO succession at Berkshire Hathaway is set to take place at year-end, but it doesn’t look like much will change, at least initially. Warren Buffett, 95, will step aside after 60 years at the helm in favor of Greg Abel, 63. The veteran Berkshire executive now heads the company’s vast non-insurance businesses.

Description: DaVita works with others in under-resourced communities to offer individualized health engagements, break down mistrust and empower action in personal health experiences. NORTHAMPTON, MA / ACCESS Newswire / December 29, 2025 / Entering a tight-knit ...

Description: Investors began to notice that Warren Buffett began being more conservative with the stock market three years ago, and that streak has continued even as the S&P 500 hit new peaks and beyond. He sold Apple (NASDAQ:AAPL), Bank of America (NYSE:BAC), VeriSign (NASDAQ:VRSN), DaVita (NYSE:DVA), D.R. Horton (NYSE:DHI), and Nucor (NYSE:NUE) as of Q3 2025. ... Buffett’s $24 Billion Selling Spree: The 6 Stocks Berkshire Hathaway Dumped

Description: In the closing of the recent trading day, DaVita HealthCare (DVA) stood at $116.51, denoting a +1.14% move from the preceding trading day.

Description: Encompass Health is in focus as outpatient and home healthcare shifts toward AI, telehealth and cost-efficient care models.

Description: NORTHAMPTON, MA / ACCESS Newswire / December 22, 2025 / DaVita: For individuals managing chronic kidney disease (CKD), dietary choices significantly impact health outcomes and disease progression. A kidney-friendly diet often involves managing intake ...

Description: DaVita (DVA) has quietly slipped this year, with the stock down about 23% year to date and roughly 24% over the past year, despite steady revenue and earnings growth. See our latest analysis for DaVita. The recent slide in DaVita’s share price, including a weaker 7 day share price return and a double digit year to date share price decline, contrasts with its solid three year total shareholder return. This suggests momentum has cooled even as the long term story remains intact. If DaVita’s...

Description: NORTHAMPTON, MA / ACCESS Newswire / December 19, 2025 / DaVita: A DaVita teammate helps organize medically tailored meals as part of a service event for Project Angel Food. From November 13-19, DaVita teammates (employees) brought the kidney care ...

Description: An aging population and rising AI adoption position the Zacks Medical - Outpatient and Home Healthcare industry for solid growth. EHC, DVA, OPCH and PNTG stand to benefit.

Description: DVA stock gets support from a patient-centric model, Q3 revenue growth and overseas expansion, even as reliance on commercial payers remains a risk.

Description: As DaVita has underperformed relative to the Dow over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.

Description: DaVita Inc. recently expanded its executive leadership team by appointing long-time leaders Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective December 11, 2025. By elevating internal talent to oversee people operations and corporate strategy, DaVita is signaling a stronger focus on culture and long-term kidney care innovation. We’ll now examine how Hendrickson’s people leadership and Phillips’s expanded strategy remit may influence DaVita’s...

Description: If you are wondering whether DaVita at around $118 a share is a bargain or a value trap, you are not alone. This breakdown is designed to help you assess the situation with more confidence. The stock is roughly flat over the last week, down about 1.2% over the past month and about 21% year to date, but still up almost 59% over three years. This combination suggests both volatility and some longer term resilience. Recently, DaVita has been in the spotlight as investors reassess defensive...

Description: DaVita, a leading provider of kidney care services, today announced two key additions to its executive leadership team: Stephanie Hendrickson has been named Chief People Officer (CPO) and Steve Phillips will serve as Chief Strategy Officer (CSO), effective immediately. Both leaders bring more than a decade of proven success at DaVita and deep expertise that will help shape the company's next chapter of growth and innovation.

Description: NORTHAMPTON, MA / ACCESS Newswire / December 2, 2025 / Approximately 129 million Americans are living with at least one chronic condition, and fragmentation of care creates a significant hurdle as these individuals often find themselves navigating ...

Description: DaVita (DVA) just finalized an amended credit agreement that brings in a $2 billion five-year term loan and a $1.5 billion revolving credit facility. This refinancing not only repays previous debt, but also offers additional financial flexibility for corporate needs. See our latest analysis for DaVita. DaVita’s recent credit agreement comes as the stock has struggled to regain its footing, with a year-to-date share price decline of 20.1% and a 12-month total shareholder return of -28%. While...

Description: DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: NORTHAMPTON, MA / ACCESS Newswire / November 28, 2025 / DaVita Earlier this year, more than 100 DaVita teammates (employees) from across the country gathered in Florida for the inaugural DaVita Recess, a two-day immersive experience designed to celebrate ...

Description: AllianceBernstein Global High Income Fund, Inc.[NYSE: AWF] (the "Fund") today released its monthly portfolio update as of October 31, 2025.

Description: The shares have been on a tear lately, buoyed by optimism about Google’s use of artificial intelligence in its search business.

Description: DaVita's consensus analyst price target has been revised downward from $147.13 to $144.50. This change signals a modest adjustment in the market's outlook. The shift reflects an ongoing reassessment of factors influencing the company's valuation, including both strengths in its business fundamentals and continuing external uncertainties. Stay tuned for guidance on how to follow future updates as DaVita's narrative continues to develop. Stay updated as the Fair Value for DaVita shifts by...

Description: Wondering if DaVita stock is trading at a bargain or an inflated premium? You are not alone, especially with so much chatter about where opportunities really lie in this market. Despite impressive gains of 62.7% across three years, DaVita’s stock has stumbled more recently, with a one-year drop of 27.3% and a decline of 19.7% year-to-date. Recent headlines have shone a spotlight on DaVita’s evolving operating environment, especially as healthcare policy debates and shifting competitive...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025, at 11:20 am EST. To view the live webcast, visit the Wolfe Research page here and create a free registration.

Description: Earlier this week, DaVita unveiled six new clinical studies at the American Society of Nephrology Kidney Week 2025 in Houston, covering advancements in dialysis treatments, middle molecule clearance, and initiatives such as GLP-1 receptor agonists for reducing hospitalizations in end-stage kidney disease patients. One standout research effort was developed through DaVita's unique program that partners with independent medical directors, helping ensure new clinical studies are deeply informed...

Description: NORTHAMPTON, MA / ACCESS Newswire / November 12, 2025 / DaVita On Nov. 13, DaVita launches its Caring Across Communities initiative, a weeklong service event dedicated to strengthening local communities across California. Through Nov. 19, nearly ...

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing . DaVita Inc. (NYSE:DVA) is one of the stocks Jim Cramer recently discussed. DaVita Inc. (NYSE:DVA) is a healthcare company that caters to the needs of kidney patients. Cramer made these remarks after co-host Carl Quintanilla discussed the […]

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Oscar Health, Inc. (NYSE:OSCR) is one of the stocks Jim Cramer recently discussed. Oscar Health, Inc. (NYSE:OSCR) is a mid-sized healthcare benefits company. It was one of the worst-hit stocks yesterday as the shares closed 17.6% lower. Cramer […]

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES

Description: DaVita has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Description: DaVita’s third quarter results drew a negative reaction from the market, as the company’s profit and margins fell short of analyst expectations despite meeting revenue forecasts. Management attributed the underperformance primarily to lower treatment volumes, which declined due to a combination of a severe flu season, the impact of Hurricane Helene, and disruptions from a cyber incident. CEO Javier Rodriguez highlighted ongoing cost management and continued investment in clinical innovation, but

Description: DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 years of

Description: Ever wondered if DaVita is actually a bargain hiding in plain sight? Let’s dive into what might be driving its current price and value story. After a solid run in recent years, DaVita’s stock is down 8.1% over the past week and has slipped 20.6% since January. This has made value-focused investors sit up and take notice. Recently, headlines have focused on changing dynamics in the U.S. healthcare sector and regulatory shifts that could impact dialysis providers. This added context helps...

Description: DaVita (DVA) shares have seen mixed trading over the past month, with the stock down around 9%. While no single headline event is driving recent moves, the company’s fundamentals have piqued investor interest. This has prompted a closer look at current valuations. See our latest analysis for DaVita. After a sharp slide in recent weeks, DaVita’s share price is now down more than 20% since the start of the year, reflecting some fading momentum. Despite this pullback, the company’s three-year...

Description: Warren Buffett's Berkshire Hathaway owns dozens of stocks, but these are the three you should pounce on.

Description: DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Description: Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.

Description: Nic Eliason: Thank you, and welcome to our third quarter conference call. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties, that could cause the actual results to differ materially from those described in the forward-looking statements.

Description: Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.

Description: DaVita HealthCare (DVA) delivered earnings and revenue surprises of -23.71% and +0.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025.

Description: ​DaVita Inc. (NYSE:DVA) is one of the Best 52-Week Low Mid Cap Stocks to Buy Now. On October 14, David MacDonald from Truist lowered the firm’s price target on DaVita Inc. (NYSE:DVA) from $148 to $140, while keeping a Hold rating on the stock. ​The analyst noted that they remain broadly bullish on the healthcare […]

Description: DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.

Description: SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc.(Nasdaq:VSEE) (the "Company"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). ...

Description: Dialysis provider DaVita Inc. (NYSE:DVA) will be announcing earnings results this Wednesday after market hours. Here’s what investors should know.

Description: AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of September 30, 2025.

Description: These bargains could prove good for your financial health.

Description: DaVita HealthCare (DVA) concluded the recent trading session at $128.05, signifying a +1.72% move from its prior day's close.

Description: DaVita will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Description: The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.